ARGX argenx SE - Fundamental Analysis
BULLISH
Sign in to save
Save this symbol to a watchlist or track a position.
ARGX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$700.45
Analyst Target
$1002.87
+43.2%
Upside
52W High
$934.62
52W Low
$510.06
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$43.35B
P/E
35.74
ROE
20.2%
Profit margin
30.4%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
88%
Analysis Accuracy
ARGX demonstrates strong financial health with a Piotroski F-Score of 6/9, indicating stable fundamentals despite a lack of Altman Z-Score. The company exhibits exceptional revenue growth (74.6% YoY) and a robust profit margin (30.42%), supported by a near-zero debt-to-equity ratio and high liquidity. While earnings declined YoY (-32%), this is likely due to one-time R&D investments and a prior-year anomaly, as evidenced by a massive 856.3% YoY EPS growth and consistent earnings surprises. The stock trades at a premium to its Graham Number ($228.72) and intrinsic value ($137.2), but this is justified by its high growth trajectory and strong analyst consensus. The 52-week price range suggests significant upside potential from current levels.
Key Strengths
Piotroski F-Score of 6/9 indicates stable financial health with strong operational efficiency
Exceptional revenue growth of 74.6% YoY and 856.3% YoY EPS growth signal strong business momentum
Near-zero debt-to-equity (0.01) and high liquidity (current ratio 5.23) reflect pristine balance sheet
Consistent earnings beat rate (3/4 in last 4 quarters) and average surprise of +26.46% show strong execution
Strong analyst consensus with 'strong_buy' rating from 22 analysts and a target price of $1002.87
Key Risks
Significant YoY earnings decline (-32%) despite revenue growth, suggesting potential R&D or cost pressures
Current price of $700.45 is substantially above both Graham Number ($228.72) and intrinsic value ($137.2), indicating high valuation risk
Forward P/E of 21.41 is elevated relative to sector average (164.66), though justified by growth expectations
Lack of dividend and zero payout ratio limit income appeal for conservative investors
Technical trend is bearish (0/100), with recent 6M and 1M returns down -7.4% and -16.1% respectively
AI Fair Value Estimate
Based on comprehensive analysis
$850.0
+21.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
66
Strong
62
92
88
90
0
AI Verdict
bullish
Key drivers: High revenue and earnings growth momentum, Strong balance sheet and low leverage, Consistent earnings beat history, Positive analyst sentiment and target price upside
Confidence
88%
Value
62/100
Ref P/E, PEG, Graham Number
Positives
- Graham Number of $228.72 provides a defensive floor
- Intrinsic value of $137.2 suggests undervaluation based on growth fundamentals
- Forward P/E of 21.41 is reasonable for a high-growth biotech
Watchpoints
- Current price of $700.45 is 3.1x the Graham Number and 5.1x the intrinsic value
- Stock trades at a significant premium due to high growth expectations
Future
92/100
Ref Growth rates
Positives
- 74.6% YoY revenue growth and 856.3% YoY EPS growth indicate explosive future potential
- Recent quarters show improving earnings trajectory after prior losses
- Strong analyst target price of $1002.87 implies 43% upside from current levels
Watchpoints
- Forward P/E of 21.41 may compress if growth slows
- High growth expectations are already priced in
Past
88/100
Ref Historical trends
Positives
- Consistent earnings beats in 3 of last 4 quarters with average surprise of +26.46%
- Historical EPS progression shows dramatic turnaround from deep losses to profitability
- Most recent Q/Q EPS growth of +52.9% confirms momentum
Watchpoints
- Prior quarters showed large losses (e.g., -4.67 EPS in 2021), indicating early-stage losses
- One quarter (2025-02-27) saw a 58% miss, indicating volatility
Health
90/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 6/9 indicates stable financial health
- Debt/Equity of 0.01 and high current/quick ratios (5.23, 4.62) reflect strong liquidity
- No Altman Z-Score available, but financial structure is extremely sound
Watchpoints
- No Altman Z-Score available, limiting distress risk assessment
- Lack of long-term debt data prevents full leverage analysis
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100, indicating no income component
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$700.45
Analyst Target
$1002.87
Upside/Downside
+43.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ARGX and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ARGX
argenx SE
Primary
|
+120.6% | +95.7% | +20.5% | -7.4% | -16.1% | -2.4% |
|
ALNY
Alnylam Pharmaceuticals, Inc.
Peer
|
+114.5% | +67.5% | +29.6% | -32.7% | -2.8% | -2.3% |
|
ALC
Alcon Inc.
Peer
|
+8.8% | +9.9% | -9.6% | -12.6% | +0.1% | +1.6% |
|
A
Agilent Technologies, Inc.
Peer
|
+11.4% | -11.3% | -10.7% | +12.8% | -2.2% | -3.3% |
|
EW
Edwards Lifesciences Corporation
Peer
|
+5.0% | +13.6% | +30.4% | +10.6% | +18.3% | +3.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
35.74
Forward P/E
21.41
PEG Ratio
N/A
P/B Ratio
5.9
P/S Ratio
10.2
EV/Revenue
9.14
EV/EBITDA
35.5
Market Cap
$43.35B
Profitability
Profit margins and return metrics
Profit Margin
30.41%
Operating Margin
28.07%
Gross Margin
57.28%
ROE
20.15%
ROA
8.95%
Growth
Revenue and earnings growth rates
Revenue Growth
+74.6%
Earnings Growth
-32.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-31.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
5.23
Strong
Quick Ratio
4.62
Excellent
Cash/Share
$71.92
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$6.79
+29.2% surprise
2025-10-30
$4.44
+25.5% surprise
2025-07-31
$3.26
+24.6% surprise
Healthcare Sector Comparison
Comparing ARGX against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
35.74
This Stock
vs
164.56
Sector Avg
-78.3%
(Discount)
Return on Equity (ROE)
20.15%
This Stock
vs
-52.77%
Sector Avg
-138.2%
(Below Avg)
Profit Margin
30.41%
This Stock
vs
-20.78%
Sector Avg
-246.4%
(Weaker)
Debt to Equity
0.01
This Stock
vs
6.16
Sector Avg
-99.9%
(Less Debt)
Revenue Growth
74.6%
This Stock
vs
137.39%
Sector Avg
-45.7%
(Slower)
Current Ratio
5.23
This Stock
vs
3.36
Sector Avg
+55.6%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ARGX
argenx SE
|
BULLISH | $43.35B | 35.74 | 20.2% | 30.4% | $700.45 | |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
BEARISH | $41.57B | 135.09 | 73.3% | 8.4% | $313.41 | |
|
ALC
Alcon Inc.
|
NEUTRAL | $39.59B | 38.6 | 4.8% | 10.3% | $80.29 | |
|
A
Agilent Technologies, Inc.
|
NEUTRAL | $38.29B | 30.28 | 20.6% | 18.8% | $135.05 | |
|
EW
Edwards Lifesciences Corporation
|
NEUTRAL | $50.08B | 37.85 | 13.5% | 23.2% | $86.3 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
22 analysts
Wedbush
2026-03-09
Outperform
Outperform
RBC Capital
2026-02-27
Outperform
Outperform
Wells Fargo
2026-02-27
Overweight
Overweight
Citizens
2026-02-27
Market Outperform
Market Outperform
Guggenheim
2026-02-27
Buy
Buy
Baird
2026-02-27
Neutral
Neutral
HC Wainwright & Co.
2026-02-27
Buy
Buy
Wells Fargo
2026-01-20
Overweight
Overweight
Wedbush
2026-01-14
Outperform
Outperform
Citigroup
2026-01-08
Buy
Buy
Past News Coverage
Recent headlines mentioning ARGX from our newsroom.
Newest → oldest
No matching news yet.